Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com

Piper Sandler reiterated an Overweight and $165 price target on Glaukos (GKOS), while the stock trades at $105.19 (implying ~57% upside to Piper's PT). The FDA approved an NDA labeling supplement enabling repeat administration of iDose TR, and analysts (BTIG to $131, Needham to $127, Stifel $160) raised targets or maintained Buys after positive iDose/Epioxa developments. Piper Sandler expects above-consensus fiscal 2026 iDose revenue and is planning H2 2026 commercialization steps (office-based field team and direct-to-consumer marketing); catalysts include sequential iDose growth from Q1 2026, though LCD reimbursement risk remains a watch item.

Analysis

The FDA-allowed repeat iDose protocol is a structural revenue amplifier: if re-administration converts even a minority of one-and-done patients into repeat customers, lifetime revenue per patient could rise by 40–100% over a 3–5 year window, converting a high fixed-cost sales model into durable, annuity-like cash flow. That dynamic favors owners of the implant platform but also creates follow-on demand for contract manufacturers and specialty polymer suppliers; expect lead times and CMO capacity to become a gating factor if adoption accelerates, with 6–12 month procurement bottlenecks possible.

Near-term growth will hinge on two operational breakpoints: payor acceptance (LCD/CMS determinations) and the commercial roll-out economics of an office-based field team plus DTC spend. Both operate on different clocks — payor decisions play out over 3–12 months and can cap achievable utilization per site, while a direct-to-consumer strategy typically requires 9–18 months to materially move referral volumes and will depress margin in year 1–2 as SG&A ramps.

Second-order competitive effects: incumbent glaucoma drug franchises face gradual erosion as procedural adoption increases, shifting dollars from chronic Rx to procedure reimbursement; ambulatory surgical centers and ophthalmic outpatient suites will capture greater share of per-patient spend, pressuring device competitors to either cut pricing or bundle services. Conversely, larger diversified eye-care device makers with broader salesforces could defend share through bundled discounts, making a targeted small-cap like GKOS vulnerable to competitor pricing reactions.

The consensus view appears to underweight early commercialization costs and payor friction while simultaneously underestimating upside from multi-dose economics. That creates a high variance outcome — substantial upside if payors and physicians accelerate repeat use, but material downside if LCDs restrict reimbursement or if CMO constraints slow supply — positioning this as a binary but asymmetric recovery story over 6–24 months.

Key Decisions for Investors

• Long GKOS equity (2–3% NAV): initiate on a confirmed pullback or post a quarterly print showing sequential iDose growth; hold 12–18 months. Risk: payor/LCD setback or slower DTC pickup; Reward: 40–60% upside if repeat-use adoption and office-rollout accelerate. Use a 15–20% stop-loss to protect capital.
• Buy a directional call spread on GKOS (12–18 month): buy the 30% OTM call and sell the 80% OTM call (notional sized at 0.5–1% NAV). Caps premium while capturing upside from successful commercial ramp; max loss = premium, upside ~2–3x if adoption accelerates.
• Pair trade to hedge med‑tech beta: long GKOS / short ALC (equal dollar, hedge ratio 1:1) for 9–12 months. Rationale: isolates idiosyncratic iDose adoption upside while shorting a large-cap eye-care incumbent that will bear pricing pressure and slower elective volume rotational risk. Trim if GKOS sells off 20% on demand/ reimbursement headlines.
• Event hedge — buy protection: allocate 0.5% NAV to out-of-the-money put options on GKOS (6–9 month) ahead of major payor/LCD decision windows. Protects against binary downside from adverse coverage rulings while retaining upside exposure through longer-dated calls or equity.